RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational...

Related Keywords

United Arab Emirates ,California ,United States ,South Korea ,Israel ,Qatar ,United Kingdom ,Kuwait ,South Africa ,Saudi Arabia ,Bahrain ,Woman ,Americans ,South Korean ,American ,Amber Fennell ,Dror Ben Asher ,Redhill Biopharma ,Bryan Gibbs ,Adi Frish ,Micha Ben Chorin ,Kukbo Co ,California Medicaid Health Care ,Ghassan Aboud Group ,Redhill Biopharma Ltd ,Nasdaq ,National Medicare Part ,Development Expenses ,Company Annual Report On Form ,Exchange Commission ,Company Expanded Access Program ,Korea Kukbo Co ,Gaelan Medical Trade ,Gulf Cooperation Council Region Saudi Arabia ,Business Development ,Chief Executive Officer ,Ben Chorin ,Chief Financial Officer ,Administrative Expenses ,Cash Used ,Operating Activities ,Cash Provided ,Financing Activities ,Net Cash Used ,Gaelan Medical ,Drug Price Competition ,Patent Term Restoration Act ,Hatch Waxman Act ,Gulf Cooperation Council ,Medicaid Health Care ,Contract Drug List ,Drug Products ,Therapeutic Equivalence Evaluations ,Hazard Ratio ,Nontuberculous Mycobacteria ,Webcast Information ,Hill Biopharma ,Private Securities Litigation Reform Act ,Expanded Access Program ,Annual Report ,Ended December ,